Literature DB >> 9840644

Therapeutic implications of interleukin-10 in surgical disease.

C H Selzman1, B D Shames, S A Miller, E J Pulido, X Meng, R C McIntyre, A H Harken.   

Abstract

Pharmacological therapy of surgical disease often involves manipulating the physiologic balance between pro- and anti-inflammatory responses. Many agents target only one aspect of the inflammatory cascade. Originally identified as a protein elaborated by T-lymphocytes, IL-10 appears to globally inhibit cytokine production. The purpose of this manuscript is to examine the immunomodulatory and anti-inflammatory effects of interleukin-10 (IL-10) in an attempt to define the clinical utility of IL-10, both as a marker of and as a therapeutic strategy for intervention in inflammatory and immune-mediated diseases. IL-10 is elaborated from multiple sources and has diverse cellular effects to regulate immune and inflammatory responses. Accumulating evidence suggests that the anti-inflammatory influence of IL-10 observed at the cellular level may be manipulated to impact the immune and inflammatory-mediated responses associated with injury and sepsis, gastrointestinal and cardiovascular disease, and transplantation. In conclusion, IL-10 is an important mediator of immune and anti-inflammatory responses in surgical disease and, as such, has therapeutic promise as an immunomodulator and as an anti-inflammatory agent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840644     DOI: 10.1097/00024382-199811000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

Review 1.  [Intensive insulin therapy in sepsis. Improvement of survival chances?].

Authors:  M G Jeschke
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  Change of TH1/TH2 cytokine equilibrium in rats with severe sepsis and therapeutic effect of recombinant interleukin-12 and Shenmai injection.

Authors:  Yong-hao Yu; Nai-qiang Cui; Qiang Fu; Jun Li
Journal:  Chin J Integr Med       Date:  2005-06       Impact factor: 1.978

3.  Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats.

Authors:  M G Jeschke; D N Herndon; R E Barrow
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

4.  Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children.

Authors:  M G Jeschke; R E Barrow; D N Herndon
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

5.  A quantitative model of thermal injury-induced acute inflammation.

Authors:  Qian Yang; Francois Berthiaume; Ioannis P Androulakis
Journal:  Math Biosci       Date:  2010-08-11       Impact factor: 2.144

Review 6.  The hepatic response to thermal injury: is the liver important for postburn outcomes?

Authors:  Marc G Jeschke
Journal:  Mol Med       Date:  2009-04-10       Impact factor: 6.354

7.  IL-1beta induces an exaggerated pro- and anti-inflammatory response in peritoneal macrophages of children compared with adults.

Authors:  Katherine A Barsness; Denis D Bensard; David A Partrick; Casey M Calkins; Richard J Hendrickson; Anirban Banerjee; Robert C McIntyre
Journal:  Pediatr Surg Int       Date:  2004-04-21       Impact factor: 1.827

8.  Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma.

Authors:  Dagmar Klein; Thomas Schubert; Raymund E Horch; Karl-Walter Jauch; Marc G Jeschke
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Insulin treatment improves the systemic inflammatory reaction to severe trauma.

Authors:  Marc G Jeschke; Dagmar Klein; David N Herndon
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

Review 10.  Regulation of chemokine expression by antiinflammatory cytokines.

Authors:  Thomas A Hamilton; Yoshihiro Ohmori; Julie Tebo
Journal:  Immunol Res       Date:  2002       Impact factor: 4.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.